https://dynamicure.com/newsroom/blockade-of-the-cd93-pathway-normalizes-tumor-vasculature-to-facilitate-drug-delivery-and-immunotherapy/2022-04-27T15:48:44-04:00https://dynamicure.com/newsroom/dynamicure-announces-ind-clearance-to-advance-first-antibody-candidate-from-its-dc-6001-anti-cd93-program-into-clinical-development/2022-11-08T10:45:10-05:00https://dynamicure.com/newsroom/dynamicure-doses-first-patients-in-phase-1-clinical-trial-of-lead-antibody-candidate-dcby02-in-advanced-cancers/2022-11-08T11:09:05-05:00